Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
398 studies found for:    "Multiple Sclerosis, Relapsing-Remitting"
Show Display Options
Rank Status Study
21 Completed Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Natalizumab;   Drug: Placebo
22 Completed Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Device: Rebif® Rebidose®;   Device: Rebiject II®
23 Withdrawn Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: RNS60 125 ml;   Drug: RNS60 250 ml;   Drug: Interferon beta 1a
24 Completed Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Rebif (Interferon beta-1a)
25 Active, not recruiting A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: Glatiramer acetate (GA);   Other: Placebo
26 Completed
Has Results
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Biological: abatacept;   Drug: Placebo
27 Terminated Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)
Condition: Multiple Sclerosis, Relapsing-remitting
Interventions: Device: RebiSmart®2.0;   Device: MSdialog™
28 Terminated Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
Condition: Relapsing-remitting Multiple Sclerosis
Intervention: Drug: Interferon beta-1b
29 Recruiting Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: IL2;   Drug: Placebo
30 Completed
Has Results
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
Condition: Relapsing Remitting Multiple Sclerosis (RRMS)
Intervention: Drug: BG00002 (natalizumab)
31 Completed Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab
32 Active, not recruiting Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
Conditions: Multiple Sclerosis, Relapsing-Remitting;   Multiple Sclerosis
Intervention: Drug: dimethyl fumarate
33 Active, not recruiting A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: interferon beta-1a;   Drug: methylprednisolone;   Drug: ocrelizumab;   Drug: placebo
34 Completed Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Natalizumab;   Drug: Placebo
35 Completed Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects
Condition: Multiple Sclerosis, Relapsing-remitting
Interventions: Device: Rebif® via Rebiject™Mini;   Device: Rebif® via manual injections
36 Recruiting A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Biological: Ocrelizumab
37 Completed An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention:
38 Completed Atorvastatin in Relapsing-Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: interferon beta treatment to add-on atorvastatin treatment;   Drug: untreated to atorvastatin treatment
39 Recruiting TMP001 in Relapsing-remitting Multiple Sclerosis
Condition: Remitting-Relapsing Multiple Sclerosis
Intervention: Drug: TMP001
40 Completed BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis
Condition: Relapsing Remitting Multiple Sclerosis
Interventions: Drug: BHT-3009 0.5 mg;   Drug: BHT-3009 1.5 mg;   Drug: Placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.